Effect of dandelion capsule on non-alcoholic fatty liver disease

Effect of dandelion capsule on improvement of liver fibrosis and liver function test among patients with non-alcoholic fatty liver disease

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20161205031252N10

Enrollment

Registered

2018-11-22

Start date

2018-11-22

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Nonalcoholic steatohepatitis. Condition 2: Fatty liver. Nonalcoholic steatohepatitis (NASH) Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: Dandelion capsule, 300 mg, oral, twice a day, for 3 months. Intervention 2: Control group: placebo capsule, oral, twice a day, for 3 months.

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Grade 2 and 3 of Non-alcoholic fatty liver Hemoglobin above 13 in male and above 12 in female

Exclusion criteria

Exclusion criteria: History of allergy to plants of asteraceae Bile duct or intestinal obstruction Diabetes and renal failure Pregnant and lactating women Weight below 50 kg Consumers of lithium, tetracyclines, fluoroquinolones, blood glucose lowering drugs and blood thinners drugs

Design outcomes

Primary

Measure	Time frame
Liver stiffness. Timepoint: Three months after treatment. Method of measurement: Fibroscan.	—

Secondary

Measure	Time frame
Blood levels of liver enzymes. Timepoint: Three months after treatment. Method of measurement: Blood test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAhmad Hormati

Ghoum University of Medical Sciences

Hormatia@muq.ac.ir+98 256122053

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026